Alkali Metals Limited (NSE: ALKALI | BSE: 533029)
Source: Alkali Metals Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Alkali Metals Limited is an established Indian specialty chemical and active pharmaceutical ingredient (API) manufacturer incorporated in 1968. Recognized as an “Export House” by the Directorate General of Foreign Trade (DGFT) and holding an approved in-house R&D facility recognized by the Department of Science & Technology (DST), Government of India, the company operates across three manufacturing locations in Telangana and Andhra Pradesh.
- Sodium Derivatives (~83% of sales volume): Sodium Amide, Sodium Alkoxides, Sodium Hydride, and Sodium Azide. These form core inputs for complex organic synthesis in bulk drug manufacturing.
- Pyridine Derivatives & Fine Chemicals (~8.5% of sales volume): Amino Pyridines, Tetrazoles, Pyridine Derivatives, and Heterocyclic Cyclic Compounds.
- Specialized & High-Value Intermediates: Intermediates targeting Cardiac (Diethyl-2ethyl-2-phenylmalonate, 2-Butylbenzofuran), Depression (4-Cyanopyrazole, 3,4-Dihydro-7-hydroxy-2(1H)-quinolinone), Diabetic / Gliptins, Oncology, HIV (2-Chloro-3-nitro-6-methoxypyridine), Agro Chemicals, and OLED/Semiconductor chemicals (2-Fluoro-4-methylpyridine, 2-Fluoropyridine).
📋 Quick Facts / Company Snapshot: Alkali Metals Limited (NSE: ALKALI | BSE: 533029)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Alkali Metals Limited |
| Corporate Identity Number (CIN) | L27109TG1968PLC001196 |
| ISIN | INE773I01017 |
| Stock Exchange Listing | BSE: 533029 | NSE: ALKALI |
| Date of Incorporation / Founding Year | 1968 |
| Founders / Key Founding Figures | Promoter Family (Second Generation: Sri Y.S.R. Venkata Rao; Third Generation: Mr. Y.V. Prashanth) |
| Registered Office & Corporate Headquarters | Plot B-5, Block III, IDA, Uppal, Hyderabad – 500 039, Telangana, India |
| Telephone & Official Investor Relations Email | Phone: +91-40-27201179, +91-40-27202298 | Email: secretarial@alkalimetals.com |
| Chairman / Managing Director & CEO | Dr. J.S. Yadav (Chairman) | Sri Y.S.R. Venkata Rao (Managing Director) |
| CFO & Company Secretary | Mrs. K.S.L. Gayathri Devi Kesavarapu (CFO) | Mr. Siddharth Dubey (Company Secretary & Compliance Officer) |
| Promoter & Holding Group | Promoter & Promoter Group (Holding 69.59% Equity Stake; Sri Y.S.R. Venkata Rao holds 67.81%) |
| Industry / Sector Classification | Chemicals & Active Pharmaceutical Ingredients (APIs) / Fine Chemicals & Intermediates |
| Total Employees / Workforce | 105 Permanent Employees as of March 31, 2026 (including 1 female employee) |
| Manufacturing Plants / Facilities Count | 3 Manufacturing Units (Unit-I: Uppal, Hyderabad; Unit-II: Dommara Pochampally, Medchal; Unit-III: JN Pharma City, Visakhapatnam) |
| Credit Ratings & Rating Agency | Long-Term Rating: BB+ (Negative); Short-Term Rating: A4+ (Reaffirmed) |
| Statutory, Secretarial & Internal Auditors | Statutory: M/s. J V S L & Associates, CAs | Secretarial: CS B. Venkatesh Babu | Internal: M/s. Ramakrishna & Associates, CAs |
| Registrar and Share Transfer Agent (RTA) | M/s. Cameo Corporate Services Limited, Chennai, Tamil Nadu |
🏢 The Corporate Identity: Alkali Metals Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Alkali Metals Limited is an established Indian specialty chemical and active pharmaceutical ingredient (API) manufacturer incorporated in 1968. Recognized as an “Export House” by the Directorate General of Foreign Trade (DGFT) and holding an approved in-house R&D facility recognized by the Department of Science & Technology (DST), Government of India, the company operates across three manufacturing locations in Telangana and Andhra Pradesh. Alkali Metals specializes in synthesizing complex chemistry platforms, including sodium derivatives, pyridine derivatives, cyclic compounds, fine chemicals, and pharmaceutical intermediates.
The company operates an integrated business model ranging from initial process chemistry research at its Hyderabad facilities to bulk commercial production for global pharmaceutical, agrochemical, and electronics clients. During FY 2025-26, Alkali Metals achieved total sales volume of 1,235 Metric Tons (MT), with exports contributing nearly half of total turnover across four continents.
The Founders, Promoters & Their Legacy
Alkali Metals Limited was founded in 1968 and has grown under the leadership of the second-generation promoter Sri Y.S.R. Venkata Rao, B.E. (Mechanical), who joined the company in 1977 and has served as Managing Director since 1991. Under his executive tenure, the company expanded its capability footprint from basic alkali metal handling to advanced sodium alkoxides, azide derivatives, and heterocyclic chemistry, while listing its equity shares on the BSE and NSE.
The promoter group holds a combined 69.59% equity stake in the company as of March 31, 2026. Sri Y.S.R. Venkata Rao personally holds 67.81% of the total share capital. The third generation of the promoter family, Mr. Y.V. Prashanth (holding a Bachelor’s Degree in Pharmacy from Andhra University and a Master’s Degree in Pharmacy from the USA), oversees corporate finance, marketing, and administration. Smt. Y. Lalithya Poorna also serves as a Non-Executive Woman Director representing the promoter group.
The Journey: Corporate History & Key Milestones
Over its 58-year corporate history, Alkali Metals has established key technological milestones in dangerous and hazardous reaction engineering within India:
- 1968: Incorporation of Alkali Metals Private Limited in Hyderabad, Telangana, focused on alkali metal chemistry.
- 1977–1991: Joining of Sri Y.S.R. Venkata Rao and commercialization of sodium amide and sodium alkoxide platforms at Unit-I (Uppal, Hyderabad).
- 2008: Initial Public Offering (IPO) and listing of equity shares on the BSE Limited and National Stock Exchange of India Limited (NSE).
- Expansion Phase: Setup and commissioning of Unit-II at Dommara Pochampally (Medchal District, Telangana) and Unit-III at JN Pharma City (Visakhapatnam, Andhra Pradesh) to support API and export-grade fine chemical lines.
- FY 2025-26: Execution of operational turnaround, registering record annual turnover of ₹93.03 Crores and net comprehensive income of ₹0.67 Crores.
The Corporate Umbrella & Group Structure
Alkali Metals Limited is a standalone operating entity. The company has no subsidiaries, associate companies, or joint venture entities in India or abroad, operating all manufacturing units and commercial activities directly under its main corporate umbrella.
⚙️ The Business Engine: Alkali Metals Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
In accordance with Ind AS 108 (Operating Segments), the company identifies geographic customer location as its primary segment reporting framework. The entire product catalog falls under the single business activity of manufacturing and selling specialty chemicals, fine chemicals, and pharmaceutical intermediates.
| Geographic Segment | FY 2025-26 Revenue (₹ Cr) | % Share of Total Revenue | FY 2024-25 Revenue (₹ Cr) | % Share of Total Revenue | Latest YoY (%) |
|---|---|---|---|---|---|
| Domestic (India) | 45.69 | 49.11% | 50.89 | 61.81% | -10.22% |
| External / Exports (Rest of World) | 47.34 | 50.89% | 31.44 | 38.19% | +50.57% |
| Total Revenue from Operations | 93.03 | 100.00% | 82.33 | 100.00% | +13.00% |
The company’s customer receivables asset base reflects its export orientation: out of total trade receivables of ₹19.41 Crores as of March 31, 2026, external export receivables accounted for ₹14.55 Crores (75.00%), while domestic receivables accounted for ₹4.85 Crores (25.00%).
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
Alkali Metals manufactured and sold 1,235 MT of finished chemical products during FY 2025-26. Product breakdown by volume share includes:
- Sodium Derivatives (~83% of sales volume): Sodium Amide, Sodium Alkoxides, Sodium Hydride, and Sodium Azide. These form core inputs for complex organic synthesis in bulk drug manufacturing.
- Pyridine Derivatives & Fine Chemicals (~8.5% of sales volume): Amino Pyridines, Tetrazoles, Pyridine Derivatives, and Heterocyclic Cyclic Compounds.
- Specialized & High-Value Intermediates: Intermediates targeting Cardiac (Diethyl-2ethyl-2-phenylmalonate, 2-Butylbenzofuran), Depression (4-Cyanopyrazole, 3,4-Dihydro-7-hydroxy-2(1H)-quinolinone), Diabetic / Gliptins, Oncology, HIV (2-Chloro-3-nitro-6-methoxypyridine), Agro Chemicals, and OLED/Semiconductor chemicals (2-Fluoro-4-methylpyridine, 2-Fluoropyridine).
Raw material sourcing relies on a combination of domestic and imported inputs. In FY 2025-26, imported raw materials totaled ₹10.33 Crores (up from ₹0.55 Crores in FY 2024-25), demonstrating international procurement for specialized chemical synthesis.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Sodium Amide & Hydride Series | Sodium Derivatives | Global API & Bulk Drug Manufacturers (Strong Base Condensation) |
| Sodium Alkoxides & Azides | Specialty Sodium Chemistry | Pharmaceutical Intermediates & Fine Chemical Synthesis |
| Amino Pyridines & Derivatives | Pyridine Chemistry | Agrochemicals & Heterocyclic Active Ingredients |
| Tetrazoles & Cyclic Compounds | Fine Chemicals | Custom Synthesis for Regulated & Emerging Pharma Markets |
Mapping the Domestic & Global Reach (India vs. Exports)
Alkali Metals has expanded its commercial distribution footprint across four continents. In FY 2025-26, export revenues rose to ₹0.47 Crores (50.89% of operational turnover), driven by higher international orders. Under its “Roadmap 2030,” the management aims to expand marketing outreach into over 30 countries—targeting enhanced penetration across Eastern Europe and China (aiming for USD 3 Million to USD 5 Million in Chinese market sales by 2030).
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The company maintains three specialized operational units in South India:
- Unit – I (Uppal, Hyderabad, Telangana): Registered Office & original manufacturing plant located at Plot B-5, Block III, IDA Uppal. Houses specialized high-pressure reaction lines and the DST-approved in-house R&D center.
- Unit – II (Dommara Pochampally, Medchal District, Telangana): Multi-purpose chemical synthesis plant located on Survey Nos. 299 to 302, supporting commercial-scale fine chemical and sodium derivative batches.
- Unit – III (JN Pharma City, Visakhapatnam, Andhra Pradesh): Specialized API and intermediate manufacturing facility spread across Plot Nos. 36, 37 & 38 inside the JN Pharma City industrial hub.
📊 The Financial Health: Alkali Metals Financial Statements & Numbers Simplified
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
The following table presents the Standalone Statement of Profit and Loss of Alkali Metals Limited for FY 2025-26 and FY 2024-25 in ₹ Crores (converted from disclosed figures in ₹ Lakhs by dividing by 100).
| Statement of Profit and Loss (in ₹ Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 93.03 | 82.33 | +13.00% |
| Other Income | 0.61 | 1.57 | -61.15% |
| Total Income | 93.64 | 83.90 | +11.61% |
| Cost of Materials Consumed | 46.48 | 39.90 | +16.49% |
| Changes in Inventories of Finished Goods & WIP | 0.60 | 3.73 | -83.91% |
| Employee Benefits Expense | 13.00 | 13.22 | -1.66% |
| Finance Costs | 2.13 | 2.51 | -15.14% |
| Depreciation and Amortization Expense | 2.89 | 4.15 | -30.36% |
| Other Expenses | 25.24 | 26.12 | -3.37% |
| Total Expenses | 90.32 | 89.62 | +0.78% |
| Profit / (Loss) Before Tax (PBT) | 3.32 | (8.04) | N/M |
| Tax Expense / (Credit) [incl. Deferred Tax & MAT Reversal] | 2.76 | (2.24) | N/M |
| Profit / (Loss) After Tax (PAT) | 0.56 | (5.80) | N/M |
| Other Comprehensive Income / (Loss) [Net of Tax] | 0.12 | (0.00) | N/M |
| Total Comprehensive Income for the Year | 0.67 | (5.80) | N/M |
Revenue from operations grew 12.99% YoY from ₹82.33 Crores in FY 2024-25 to ₹93.03 Crores in FY 2025-26. Operational optimization and expense control allowed the company to generate a PBT of ₹3.32 Crores, compared to a PBT loss of ₹8.04 Crores (which included ₹2.31 Crores of exceptional items) in the prior fiscal year. Total comprehensive income turned positive at ₹0.67 Crores.
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
The Statement of Assets, Liabilities, and Equity as of March 31, 2026 and March 31, 2025 is set out below in ₹ Crores:
| Balance Sheet (in ₹ Crores) | As at Mar 31, 2026 | As at Mar 31, 2025 | Latest YoY (%) |
|---|---|---|---|
| Property, Plant and Equipment | 38.46 | 41.03 | -6.26% |
| Other Non-Current Financial Assets & MAT Credit | 3.89 | 5.91 | -34.18% |
| Total Non-Current Assets | 42.35 | 46.94 | -9.78% |
| Inventories | 28.84 | 26.69 | +8.06% |
| Trade Receivables | 19.41 | 14.34 | +35.36% |
| Cash and Cash Equivalents | 0.05 | 0.04 | +25.00% |
| Bank Balances other than Cash & Cash Equivalents | 0.94 | 0.57 | +64.91% |
| Other Financial & Current Assets | 3.95 | 4.35 | -9.20% |
| Total Current Assets | 53.20 | 46.00 | +15.65% |
| TOTAL ASSETS | 95.55 | 92.94 | +2.81% |
| Equity Share Capital | 10.18 | 10.18 | 0.00% |
| Other Equity | 34.51 | 34.34 | +0.50% |
| Total Equity (Net Worth) | 44.69 | 44.52 | +0.38% |
| Non-Current Borrowings | 0.00 | 0.23 | -100.00% |
| Provisions, Deferred Tax & Other Non-Current Liabilities | 3.88 | 2.84 | +36.62% |
| Total Non-Current Liabilities | 3.88 | 3.07 | +26.38% |
| Current Borrowings | 17.85 | 17.69 | +0.90% |
| Trade Payables | 26.27 | 19.25 | +36.47% |
| Other Financial & Current Liabilities & Provisions | 2.86 | 8.40 | -65.95% |
| Total Current Liabilities | 46.98 | 45.34 | +3.62% |
| Total Liabilities (Excluding Equity) | 50.86 | 48.41 | +5.06% |
| TOTAL EQUITY AND LIABILITIES | 95.55 | 92.94 | +2.81% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
Management monitors working capital efficiency through standard operating metrics. Key financial ratios and explanations for major variances (exceeding 25% YoY) disclosed under Schedule III include:
| Financial Ratio | FY 2025-26 | FY 2024-25 | Management Explanation for Significant Variance | Latest YoY (%) |
|---|---|---|---|---|
| Current Ratio | 1.13 | 1.02 | Improved current asset build-up in receivables and inventories. | +10.78% |
| Debt-Equity Ratio | 0.52 | 0.52 | Stable debt structure relative to equity base. | 0.00% |
| Debt Service Coverage Ratio (DSCR) | 2.36 | 0.80 | Operational profit recovery strengthening cash available for debt service. | +195.00% |
| Return on Equity (ROE) | 1.25% | 13.03% | Positive net profit generated in FY 2025-26 versus loss in FY 2024-25. | – |
| Inventory Turnover Ratio | 1.70 | 1.44 | Higher production velocity and increased finished goods off-take. | +18.06% |
| Trade Receivables Turnover Ratio | 5.51 | 5.10 | Faster collection cycles across customer base. | +8.04% |
| Net Capital Turnover Ratio | 14.73 | 108.90 | Substantial expansion in net working capital base (working capital rose to ₹6.22 Cr). | -86.47% |
| Return on Capital Employed (ROCE) | 9.96% | 14.92% | Recovery in operating profit (EBIT) driven by export volume gains. | – |
Cash Flow: Tracking the Money Movement
The cash flow movements for FY 2025-26 and FY 2024-25 are summarized below in ₹ Crores:
| Cash Flow Summary (in ₹ Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated from Operating Activities | 2.82 | 5.25 | -46.29% |
| Purchase of PPE / CapEx (Investing Activity) | 0.32 | 1.31 | -75.57% |
| Net Cash from / (Used in) Investing Activities | (0.27) | (0.75) | -64.00% |
| Dividends Paid (Financing Activity) | (0.51) | (1.02) | -50.00% |
| Net Cash Used in Financing Activities | (2.54) | (4.50) | -43.56% |
| Net Increase in Cash & Cash Equivalents | 0.01 | 0.00 | N/M |
| Cash & Cash Equivalents at End of Year | 0.05 | 0.04 | +25.00% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
During FY 2025-26, additions to Property, Plant, and Equipment (CapEx) totaled ₹0.32 Crores (down from ₹1.31 Crores in FY 2024-25). The company spent ₹1.25 Crores on Research & Development during the year (representing 1.34% of turnover), focusing on high-efficiency yield processes for sodium and pyridine derivatives.
Net foreign exchange earnings for FY 2025-26 reached ₹0.36 Crores, based on export inflows of ₹0.47 Crores offset by total foreign currency outgo of ₹10.92 Crores (primarily ₹10.33 Crores of imported raw materials).
👥 Power & Control: Alkali Metals Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Dr. J.S. Yadav | Chairman | 02014136 | Non-Executive & Non-Independent Director |
| Sri Y.S.R. Venkata Rao | Managing Director | 00345524 | Executive Director (Promoter) |
| Sri K.V. Suryaprakash Rao | Director | 06934146 | Independent Director |
| Sri Murali Krishna Chevuturi | Director (resigned w.e.f. June 8, 2026) | 01770851 | Independent Director |
| Dr. T.V. Rao | Director | 05273533 | Independent Director |
| Sri G. Jayaraman | Director | 01461157 | Non-Executive & Non-Independent Director |
| Dr. A.R. Prasad | Director | 08765436 | Non-Executive & Non-Independent Director |
| Smt. Y. Lalithya Poorna | Director | 00345471 | Non-Executive Woman Director (Promoter Group) |
| Mr. Y.V. Prashanth | Executive Director | 00345418 | Executive Director (Promoter Group) |
| Sri Sivarama Prasad Bhamidi | Director (proposed w.e.f. July 20, 2026) | 07620679 | Independent Director |
| Mrs. K.S.L. Gayathri Devi Kesavarapu | Chief Financial Officer | – | Key Managerial Personnel (KMP) |
| Mr. Siddharth Dubey | Company Secretary & Compliance Officer | – | Key Managerial Personnel (KMP) |
Who Owns the Stock? Shareholding Pattern
| Shareholder Category | Number of Shareholders | Number of Shares Held | % of Total Issued Capital |
|---|---|---|---|
| Promoter & Promoter Group | 5 | 70,85,842 | 69.59% |
| Resident Individuals (Public) | 12,534 | 28,86,555 | 28.35% |
| Hindu Undivided Families (HUFs) | 187 | 1,05,238 | 1.03% |
| Non-Resident Indians (NRIs) | 135 | 55,289 | 0.54% |
| Bodies Corporate (Public) | 42 | 23,434 | 0.23% |
| Investor Education & Protection Fund (IEPF) | 1 | 23,147 | 0.23% |
| Limited Liability Partnerships (LLPs) | 2 | 3,001 | 0.03% |
| Total Issued Share Capital | 12,906 | 1,01,82,506 | 100.00% |
The promoter entity Sri Y.S.R. Venkata Rao individually holds 69,04,715 shares (67.81%). As of March 31, 2026, 99.99% of total equity shares were dematerialized (81.43% in NSDL and 18.56% in CDSL), with only 508 physical shares outstanding.
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
As disclosed in the Director’s Report, Alkali Metals Limited does not have any subsidiaries, associate companies, or joint ventures. Consequently, reporting under Form AOC-1 is not applicable.
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
The company maintains working capital credit facilities backed by primary and collateral security with State Bank of India (SME Yellareddy Guda Branch, Hyderabad). Outstanding bank credit ratings provided by rating agencies as of FY 2025-26 are:
- Long-Term Credit Rating: BB+ (Negative)
- Short-Term Credit Rating: A4+ (Reaffirmed)
Contingent liabilities not provided for in the balance sheet as of March 31, 2026 totaled ₹0.49 Crores, as broken down below:
- Customs Duty (Unfulfilled Export Obligations): ₹0.15 Crores
- GST Disputed Demands (Telangana & Andhra Pradesh under Appeal): ₹0.18 Crores
- Income Tax Disputed Matters (AY 2017-18 & AY 2018-19): ₹0.14 Crores
- Bank Guarantees Outstanding: ₹0.04 Crores (₹0.0400 Crores)
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Alkali Metals operates with key industrial entry barriers:
- Specialized Reaction Capabilities: Over five decades of expertise handling reactive alkali metals, sodium amide chemistry, and explosive azide intermediates, requiring controlled industrial safety systems.
- In-House R&D Base: DST-recognized R&D center developing indigenous batch automation and byproduct recycling loops (such as hydrogen and nitrous oxide recovery plants across operating units).
- Global Regulatory & Export Audit Footprint: Approved supplier status across global pharmaceutical clients in over 20 countries, supported by ECGC credit insurance coverage.
What Could Go Wrong? Key Challenges & Business Risks
Key risk factors outlined by management include:
- Geopolitical & Logistics Headwinds: Shipping disruptions and regional conflicts in West Asia, requiring bill-and-hold inventory arrangements for overseas customers.
- Raw Material Price Volatility: Direct vulnerability to cost fluctuations in imported chemical raw materials (imported raw materials rose to ₹10.33 Crores in FY 2025-26).
- Foreign Exchange Risk: Unhedged net export revenues subject to foreign currency fluctuations.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Under its strategic plan “Roadmap 2030,” Alkali Metals is expanding its molecular chemistry pipeline into high-value market segments, including semiconductor and OLED materials (such as 2-Fluoro-4-methylpyridine), agrochemical intermediates, and oncology/cardiac active ingredients. Commercial targets include expanding geographic presence to over 30 countries and scaling Chinese market sales to USD 5 Million by 2030.
The Verdict: Strategic Outlook & Conclusion
With an operational turnaround achieved in FY 2025-26—delivering revenue growth of 12.99% to ₹93.03 Crores and a return to profitability—Alkali Metals Limited has re-established positive cash generation. Backed by a 69.59% promoter holding, dedicated manufacturing units in Telangana and Andhra Pradesh, and a DST-recognized R&D facility, the company remains positioned to capture rising demand across global pharmaceutical and specialty chemical supply chains.
Frequently Asked Questions (FAQs) About Alkali Metals
Q1: What does Alkali Metals Limited manufacture?
Alkali Metals Limited manufactures sodium derivatives (Sodium Amide, Sodium Hydride, Sodium Azide, Sodium Alkoxides), pyridine derivatives, tetrazoles, cyclic fine chemicals, active pharmaceutical ingredients (APIs), and specialty intermediates used in cardiac, diabetic, oncology, agrochemical, and electronics applications.
Q2: What were Alkali Metals’ revenue and net profit figures in FY 2025-26?
In FY 2025-26, Alkali Metals achieved total revenue from operations of ₹93.03 Crores and net profit after tax (PAT) of ₹0.56 Crores (with total comprehensive income of ₹0.67 Crores), compared to revenue of ₹82.33 Crores and a net loss of ₹5.80 Crores in FY 2024-25.
Q3: Who are the main promoters and executives of Alkali Metals?
The company is led by second-generation promoter Sri Y.S.R. Venkata Rao (Managing Director) and Dr. J.S. Yadav (Chairman). The promoter group holds 69.59% of the equity capital, with Sri Y.S.R. Venkata Rao holding a 67.81% direct stake.
Q4: Where are the company’s manufacturing units located?
Alkali Metals operates three manufacturing units in South India: Unit-I at Uppal (Hyderabad, Telangana), Unit-II at Dommara Pochampally (Medchal District, Telangana), and Unit-III at JN Pharma City (Visakhapatnam, Andhra Pradesh).
Q5: What is the debt profile and credit rating of Alkali Metals as of FY 2025-26?
The company had total debt of ₹17.85 Crores (primarily short-term working capital borrowings) against a Net Worth of ₹44.69 Crores as of March 31, 2026, resulting in a Debt-to-Equity ratio of 0.52. Its credit ratings are BB+ (Negative) for long-term facilities and A4+ (Reaffirmed) for short-term facilities.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.alkalimetals.com